These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 30406819)

  • 21. Renoprotective effect of calcium channel blockers in combination with an angiotensin receptor blocker in elderly patients with hypertension. A randomized crossover trial between benidipine and amlodipine.
    Miyagawa K; Dohi Y; Nakazawa A; Sugiura T; Yamashita S; Sato K; Kimura G
    Clin Exp Hypertens; 2010 Jan; 32(1):1-7. PubMed ID: 20144066
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Morning home blood pressure may be a significant marker of nephropathy in Japanese patients with type 2 diabetes: ADVANCED-J study 1.
    Tanaka Y; Daida H; Imai Y; Miyauchi K; Sato Y; Hiwatari M; Kitagawa A; Kishimoto J; Yamazaki T; Kawamori R
    Hypertens Res; 2009 Sep; 32(9):770-4. PubMed ID: 19557003
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of combination antihypertensive therapy with low-dose indapamide: assessment by blood pressure self-monitoring at home.
    Hashimoto J; Hirayama H; Hanasawa T; Watabe D; Asayama K; Metoki H; Kikuya M; Ohkubo T; Totsune K; Imai Y
    Clin Exp Hypertens; 2005 May; 27(4):331-41. PubMed ID: 15921070
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial.
    Ogihara T; Fujimoto A; Nakao K; Saruta T;
    Expert Rev Cardiovasc Ther; 2008 Oct; 6(9):1195-201. PubMed ID: 18939907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups.
    Assaad-Khalil SH; Najem R; Sison J; Kitchlew AR; Cho B; Ueng KC; DiTommaso S; Shete A
    Vasc Health Risk Manag; 2015; 11():71-8. PubMed ID: 25653536
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiotensin receptor blocker (ARB)-diuretic versus ARB-calcium channel blocker combination therapy for hypertension uncontrolled by ARB monotherapy.
    Oshikawa J; Toya Y; Morita S; Taguri M; Hanaoka K; Hasegawa T; Kaizu K; Kamata K; Kobayashi S; Ohtake T; Sato T; Yasuda G; Kimura K; Umemura S
    Clin Exp Hypertens; 2014; 36(4):244-50. PubMed ID: 23848219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amlodipine versus angiotensin II receptor blocker; control of blood pressure evaluation trial in diabetics (ADVANCED-J).
    Kawamori R; Daida H; Tanaka Y; Miyauchi K; Kitagawa A; Hayashi D; Kishimoto J; Ikeda S; Imai Y; Yamazaki T
    BMC Cardiovasc Disord; 2006 Oct; 6():39. PubMed ID: 17029631
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of single-pill irbesartan/amlodipine combination-based therapy on clinic and home blood pressure profiles in hypertension with chronic kidney diseases.
    Kobayashi R; Tamura K; Wakui H; Ohsawa M; Azushima K; Haku S; Uneda K; Ohki K; Haruhara K; Kinguchi S; Umemura S
    Clin Exp Hypertens; 2016; 38(8):744-750. PubMed ID: 27936999
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The therapeutic advantage of combination antihypertensive drug therapy using amlodipine and irbesartan in hypertensive patients: Analysis of the post-marketing survey data from PARTNER (Practical combination therapy of Amlodin and angiotensin II Receptor blocker; safety and efficacy in patients with hypertension) study.
    Ishimitsu T; Fukuda H; Uchida M; Ishibashi K; Sato F; Nukui K; Nagao M
    Clin Exp Hypertens; 2015; 37(7):542-50. PubMed ID: 25978131
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Titration of telmisartan, but not addition of amlodipine, reduces urine albumin in diabetic patients treated with telmisartan-diuretic.
    Kojima M; Ohashi M; Dohi Y; Kimura G
    J Hypertens; 2013 Jan; 31(1):186-91. PubMed ID: 23047595
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.
    Ogawa H; Kim-Mitsuyama S; Matsui K; Jinnouchi T; Jinnouchi H; Arakawa K;
    Am J Med; 2012 Oct; 125(10):981-90. PubMed ID: 22503610
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined effect of angiotensin II receptor blocker and either a calcium channel blocker or diuretic on day-by-day variability of home blood pressure: the Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study.
    Matsui Y; O'Rourke MF; Hoshide S; Ishikawa J; Shimada K; Kario K
    Hypertension; 2012 Jun; 59(6):1132-8. PubMed ID: 22547439
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of combination therapy of angiotensin-converting enzyme inhibitor plus calcium channel blocker on urinary albumin excretion in hypertensive microalbuminuric patients with type II diabetes.
    Shigihara T; Sato A; Hayashi K; Saruta T
    Hypertens Res; 2000 May; 23(3):219-26. PubMed ID: 10821130
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of olmesartan, an angiotensin II receptor blocker, and amlodipine, a calcium channel blocker, on Cardio-Ankle Vascular Index (CAVI) in type 2 diabetic patients with hypertension.
    Miyashita Y; Saiki A; Endo K; Ban N; Yamaguchi T; Kawana H; Nagayama D; Ohira M; Oyama T; Shirai K
    J Atheroscler Thromb; 2009 Oct; 16(5):621-6. PubMed ID: 19907103
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effective and safe reduction of blood pressure with the combination of amlodipine 5 mg and valsartan 160 mg in hypertensive patients not controlled by calcium channel blocker monotherapy.
    Brachmann J; Ansari A; Mahla G; Handrock R; Klebs S
    Adv Ther; 2008 May; 25(5):399-411. PubMed ID: 18465097
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.
    Shimada K; Ogihara T; Saruta T; Kuramoto K;
    Clin Ther; 2010 May; 32(5):861-81. PubMed ID: 20685495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Tolerability of Combination Therapy Versus Monotherapy with Candesartan and/or Amlodipine for Dose Finding in Essential Hypertension: A Phase II Multicenter, Randomized, Double-blind Clinical Trial.
    Sohn IS; Kim CJ; Ahn T; Youn HJ; Jeon HK; Ihm SH; Cho EJ; Chung WB; Chae SC; Kim WS; Nam CW; Park SM; Choi JY; Kim YK; Hong TJ; Lee HY; Cho JH; Shin ES; Yoon JH; Yang TH; Jeong MH; Lee JH; Park JI
    Clin Ther; 2017 Aug; 39(8):1628-1638. PubMed ID: 28734660
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [On the way to achieve hypertension treatment goals: results of the open observational program AESCULAP (exforge--clinical safety and efficiency of using a double combination of antihypertensive drugs in patients with uncontrolled blood pressure)].
    Chazova IE; Martynyuk TV
    Ter Arkh; 2013; 85(9):35-45. PubMed ID: 24261228
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fixed-Dose Triple Combination of Antihypertensive Drugs Improves Blood Pressure Control: From Clinical Trials to Clinical Practice.
    Mazza A; Lenti S; Schiavon L; Sacco AP; Dell'Avvocata F; Rigatelli G; Ramazzina E
    Adv Ther; 2017 Apr; 34(4):975-985. PubMed ID: 28299716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.